Fiche centre
University Of Maryland
Baltimore — United States
Essais liés7clinical trials
VilleBaltimorelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05624749
Essais cliniques associés
7| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Inavolisib | Cancer | Phase 3 | NCT06790693 | INAVO123 — A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | RECRUITING |
| T2:C100 | Alzheimer | Phase 2 | NCT05644262 | LiBBY — Life's End Benefits of cannaBidiol and tetrahYdrocannabinol | COMPLETED |
| NEU-411 | Parkinson | Phase 2 | NCT06680830 | NEULARK — A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | RECRUITING |
| Ianalumab | Lupus | Phase 3 | NCT05624749 | Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) | ACTIVE_NOT_RECRUITING |
| Eptinezumab | Migraine | Phase 3 | NCT04965675 | PROSPECT-2 — A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | RECRUITING |
| APL-130277 | Parkinson | Phase 3 | NCT02542696 | Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease | COMPLETED |
| Ianalumab | Lupus | Phase 3 | NCT06133972 | Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). | RECRUITING |